Does Inhaled Cannabis Reduce Pain in Adults With Sickle Cell Disease?
Investigators aimed to determine whether vaporized cannabis would reduce symptoms of chronic pain in adult patients with sickle cell disease.
Leukemia
LEUKEMIA
FEATURE
LATEST ARTICLES
Survivors of Adolescent, Young Adult ALL May Suffer Late Effects
Estimated 10-year cumulative incidence high for subsequent endocrine disease, cardiac disease.
Identifying Risk Factors for Invasive Fungal Infection in Ibrutinib-Treated CLL Patients
Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.
MPN Genomic Calculator Performs Well in Real-Life Cohort of Patients With Essential Thrombocythemia
The MPN Genomic Calculator uses clinical, laboratory, and genomic characteristics of patients with MPN to estimate their clinical outcomes.
Sorafenib Maintenance Therapy After Allo-HSCT Improves Outcomes in FLT3-ITD–Positive AML
Among patients with FLT3-internal tandem repeats, sorafenib maintenance therapy reduces the risk of relapse and death after allo-HSCT.
Genetic Prognostic Factors in CLL Treated With Novel Compounds
Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus chlorambucil, regardless of the presence of unfavorable genetic prognostic factors.
Dental Screenings Prior to Induction Chemotherapy for Acute Myeloid Leukemia
Researchers found that identifying and treating acute odontogenic disease before induction chemotherapy prevented infectious dental emergencies in AML patients.
Allogeneic-HSCT Outcomes With Varied Donor Sources in Adult T-Cell Leukemia/Lymphoma
Researchers studied the pros and cons of transplantation from different donor sources to enhance overall outcomes of allo-HSCT in adults with T-cell malignancies.
AEs From Ibrutinib in Real-World CLL: More Research Needed
Some tyrosine kinase inhibitors may cause a hyperinflammatory response.
Risk-Adapted Therapy Prevents Fungal Infections in Childhood Leukemia
Risk-adapted therapy effectively prevents fungal infections and reduces neurotoxicity in children with leukemia.
Subset of Patients With Richter Syndrome May Obtain Long-Term Survival
Data from Spain add to the knowledge of Richter syndrome.
Ofatumumab Plus Hyper-CVAD for Newly Diagnosed (Ph)-Negative, CD20-Positive B-Cell ALL
Combined ofatumumab and hyper-CVAD is a safe and active treatment for adult patients with (Ph)-negative, CD20-positive B-cell ALL.
Changes in Management of CLL Due to COVID-19 Noted in Italy
The management of CLL, including delays in work-up and treatment, and modifications to clinical trials, have been implemented across Italy in response to the COVID-19 pandemic.
Trial Evaluating Pracinostat in AML Patients Unfit for Intensive Chemotherapy Discontinued
Helsinn and MEI Pharma have discontinued a phase 3 study evaluating pracinostat, in combination with azacitidine, for frontline treatment of older patients with acute myeloid leukemia.
AML: Adding Venetoclax to LDAC May Improve Outcomes in Newly Diagnosed Patients
At primary analysis, 40% of patients assigned to the venetoclax arm vs 31% of those assigned to placebo were alive.
Treating Strategies for Patients With Relapsed/Refractory Acute Myeloid Leukemia
Although numerous clinical studies have aimed to treat AML, most results have been disappointing, according to authors of a publication in Blood.
Treatment, Remaining Needs Pertaining to Acute Myeloid Leukemia
The current state of AML treatment and remaining needs are discussed in an interview with Courtney D. DiNardo, MD, MSCE and Ghayas C. Issa, MD.
Good Diet May Cut Toxicity Risk in Treatment of Pediatric ALL
Greater intake of foods rich in antioxidants tied to lower rates of infection, mucositis during treatment.
Study Finds Higher Incidence of Atrial Fibrillation With Ibrutinib Therapy
Patients with chronic lymphocytic leukemia who are treated with ibrutinib may have a higher incidence of atrial fibrillation than previously thought.
Benefit From CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell ALL
Patients with B-cell ALL who are treated with CAR T-cell therapy and allo-HSCT may have better outcomes than those treated only with CAR T-cell therapy.
Immunoglobulin Assessment For Stratifying Prognosis, Target Therapy in AML
For patients with AML, high immunoglobulin expression is linked to monocytic differentiation, dysplasia, and poorer prognosis.
Loss of Limb Mobility in a Patient With T-ALL Treated With Nelarabine
In this patient case, significant neurological adverse effects associated with nelarabine were noted at 30 days following initiation of therapy.
Disease-Free Survival Not Improved With Intrathecal Triple Therapy in B-Cell ALL
A study compared the effects of intrathecal triple therapy to intrathecal methotrexate on disease-free survival among patients with B-ALL.
Mylotarg Indication Expanded to Include Newly-Diagnosed Pediatric AML
The FDA has expanded the approval of Mylotarg (gemtuzumab ozogamicin; Pfizer) to include treatment of patients aged 1 month and older with newly-diagnosed CD33-positive acute myeloid leukemia.
FLT3-ITD With an Insertion Site in the Beta1-Sheet Prognostic for Poor Outcomes in AML
Among adult patients with newly diagnosed AML, the presence of an FLT3-ITD mutation with an insertion site in the beta1-sheet was associated shorter survival.
Chemotherapy-Free Regimen Consisting of 3 Novel Agents for Previously Untreated, Poor Prognosis CLL
In this study, obinutuzumab, ibrutinib, and venoclax were administered as first-line therapy in patients with CLL characterized by del(17p) and/or TP53 mutation.
Addition of Venetoclax to Azacitidine Associated With Clinically Significant OS Benefit in AML
The addition of venetoclax to azacitidine was associated with a 34% reduction in risk of death.
Venetoclax Plus Low-Dose Cytarabine Improved OS in Untreated AML Ineligible for Intense Chemotherapy
In an updated analysis, venetoclax plus low-dose cytarabine improved OS compared with placebo among patients with untreated AML who were ineligible for intense chemotherapy.
Does Acalabrutinib Improve Outcomes in Relapsed/Refractory CLL?
For patients with r/r CLL, acalabrutinib significantly improved progression-free survival compared with idelalisib-rituximab or bendamustine-rituximab.
Results of GO-CLLEAR Study in Patients With Chronic Lymphocytic Leukemia
Investigators compare efficacy and safety of obinutuzumab/chlorambucil, rituximab/ chlorambucil, and rituximab/bendamustine as frontline CLL treatments.
Improved Risk Stratification Models Needed to Predict Baseline Risk of Tumor Lysis Syndrome in Relapsed CLL Treated With Venetoclax
In this study, the incidence of laboratory tumor lysis syndrome was 13% in a cohort of patients with relapsed CLL treated with venetoclax in a “real world” setting.
Fixed-Duration Venetoclax-Obinutuzumab for Untreated Chronic Lymphocytic Leukemia
Promising follow-up data on safety and efficacy of fixed-duration venetoclax-obinutuzumab for patients with untreated CLL.
Understanding Patient Needs May Increase Treatment Rates in AML
Physicians noted that patients receiving best supportive care were more likely to be interested in low-intensity treatments if the risk for side effects was lower.
Risk of Secondary AML May Be Increasing Among Patients With Refractory Anemia
Despite survival improvements in refractory anemia compared with other subtypes of MDS, patients may still have an increased risk for secondary AML.
Durable Long-Term Responses in B-cell Lymphoma and Chronic Lymphocytic Leukemia After Anti-CD19 CAR T-Cell Therapy
Researchers reported long-term follow up from the first clinical trial of anti-CD19 CAR T cells that revealed responses against lymphoma.
Novel Pediatric Disease Risk Index in Patients With ALL, AML for Allogeneic Hematopoietic Cell Transplantation
Researchers outlined a validated p-DRI for AML and ALL that successfully stratifies children undergoing allogeneic hematopoietic cell transplantation for prognostication.
Anti-CD117 CAR T Cells Promising Immunotherapeutic Modality for AML
Generating CAR T cells against human cognate receptor CD117 may be a successful treatment for patients with AML.
Phase 2 Study of CPX-351 Results Promising in Relapsed Pediatric AML
Encouraging response rates in children with first relapse AML treated with CPX-351 followed by FLAG provide rationale for de novo AML study.
Study Links DLBCL and CLL Incidence to Race and Ethnicity, Urban Status
The incidence of DLBCL among Hispanic individuals and CLL among non-Hispanic black individuals was associated with urban status.
Novel Therapies Needed: Poor Prognosis of Patients With TP53-Mutated Myeloid Malignancies
Novel treatment options are needed to improve outcomes for patients with TP53-mutated myeloid neoplasms.
Gene Expression Approach Using Residual Cells Feasible for Future CLL Studies
Two extraction and amplification methods for gene expression analyses on residual leukemic cells may improve future studies when working with fewer cells.
Study Findings Support Long-Term Efficacy and Safety of Acalabrutinib in R/R CLL
Based on results of pharmacodynamics analyses, the phase 2 study protocol was amended to only include a 100 mg, twice-daily dosing of acalabrutinib.
Dexrazoxane Reduces Short-Term Anthracycline-Associated Cardiac Dysfunction in Pediatric AML
Pediatric patients with AML may benefit from dexrazoxane as a cardioprotectant during first-line anthracycline therapy.
Real-World Outcomes for Patients With CLL Differ in Community Setting
The Connect CLL Registry revealed that real-world treatment outcomes for patients with CLL who were treated in the community setting differed from trial results.
Smoking Tied to Inferior Survival in Acute Myeloid Leukemia
Smoking associated with inferior survival among patients receiving intensive chemotherapy for AML.
Higher Dose of CAR-T May Improve Efficacy in Relapsed/Refractory CLL
A higher dose of anti-CD19 CAR-T resulted in similar toxicities, but higher ORR and longer PFS, compared with a lower dose in patients with relapsed/refractory CLL.
Acalabrutinib as Potential First-Line Therapy for Chronic Lymphocytic Leukemia
Acalabrutinib, administered as monotherapy or in combination with obinutuzumab, may be an effective first-line therapy to improve outcomes in CLL.
First-in-Human Universal CAR-T Therapy Found Active in Relapsed/Refractory T-ALL
A first-in-human, universal CAR-T therapy was tolerable and showed activity against relapsed/refractory T-ALL in a phase 1 study.
Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL
A novel, bispecific CD19/CD22 CAR-T therapy was tolerable and led to responses in a phase 1, dose-escalating study.
MUC4 Overexpression and Prognosis in Acute Myeloid Leukemia
Increased bone marrow MUC4 expression is associated with reduced remission persistence and exacerbated survival in patients with acute myeloid leukemia.
Imbruvica Plus Rituximab Approved for Chronic Lymphocytic Leukemia
The FDA has approved the supplemental New Drug Application for Imbruvica® (ibrutinib;Janssen) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Leukemia
